Triazolam NDC 70710-1521

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1521Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1521Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
70710-1521-1	70710152101	100 TABLET in 1 BOTTLE (70710-1521-1)Marketed from Dec 30, 2022
70710-1521-5	70710152105	500 TABLET in 1 BOTTLE (70710-1521-5)Marketed from Dec 30, 2022
70710-1521-8	70710152108	10 TABLET in 1 BOTTLE (70710-1521-8)Marketed from Dec 30, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Triazolam
Generic name (nonproprietary): triazolam
Active ingredients: Triazolam — .125 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213003
Marketing start: Dec 30, 2022
Listing expires: Dec 31, 2026
DEA schedule: CIV
Other FDA classes: Benzodiazepines (Chemical structure)
Identifiers: Product ID 70710-1521_4c2fb12f-623b-4dc9-a9e0-7fac953f5cf0SPL ID 4c2fb12f-623b-4dc9-a9e0-7fac953f5cf0SPL set ID 8d414eb8-eec9-486f-90fc-00eed0cf7dafRxCUI 198317, 198318UNII 1HM943223RUPC 0370710128913, 0370710152116
Pharmacologic class: Benzodiazepine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710152101 followed by a unit qualifier and the quantity

Package 70710-1521-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 10, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Triazolam tablets are indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam tablets are a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213003

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213003
Product	Strength	Form · route	Labeler	Product NDC
Triazolam	Triazolam .125 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1576
Triazolam	Triazolam .25 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1162
Triazolam	Triazolam .25 mg/1	TabletOral	Zydus Pharmaceuticals USA Inc.	70710-1289
Triazolam	Triazolam .25 mg/1	TabletOral	A-S Medication Solutions	50090-7787